Search results
Results from the WOW.Com Content Network
Aclidinium bromide is a long-acting, inhaled muscarinic antagonist (LAMA) approved in the United States in July 2012 [3] as a maintenance treatment for chronic obstructive pulmonary disease (COPD). [4] Evidence shows that it can improve quality of life and prevent hospitalization in those with COPD. [5]
Past clinical studies have shown users of the medications can lose between 5% and 20% of their body weight on the medications over time. The most commonly reported side effects of medications used ...
Aclidinium bromide/formoterol, sold under the brand names Duaklir and Brimica, is a fixed-dose combination medication for inhalation, used in the management of chronic obstructive pulmonary disease (COPD). [5] It consists of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol, a long-acting β 2 agonist. [3] [4]
Inhaled short-acting β2-adrenergic agonists, such as terbutaline and salbutamol, are the first-line drugs indicated for asthma exacerbation for all patients to provide rapid bronchodilating effects. [ 1 ] [ 2 ] Short-acting β2-adrenergic agonists can be delivered by different devices, for example, nebulizers and metered-dose inhalers .
The Basics of Losing Weight After 40. Losing weight can be challenging at the best of times. But after the big 4-0, a few more challenges pop up, making weight gain common and weight loss harder.
“Noom is a mobile app-based weight loss program that focuses on building long-term, sustainable healthy habits,” Castro explains. “It teaches users to recognize patterns, habits, and ...
Side effects [29] [43] Mostly related to long-term administration; Adrenocortical insufficiency; Fluid retention; Weight gain; Bone loss (osteoporosis) Cataract; Diabetes; Used in acute exacerbation; Usually used for 5 days; Can be used orally or by intravascular injection; It can be abruptly discontinued without any tapering [28] Caution [29]
Umeclidinium bromide is a long-acting muscarinic antagonist. [14] This combination was approved by the FDA on December 18, 2013 [ 15 ] for the long-term maintenance treatment of COPD. On March 28, 2014, it was approved in European countries [ 16 ] and in Russia [ 17 ] under the same trade name.